Japanese drugmaker Astellas Pharma (TYO: 4503) has posted first-half sales for fiscal 2015/2016 up 15.7% year-on-year boosted by a stronger yen.
The company reported sales of 687.5 million yen ($5.7 million) compared with 594.5 million a year ago. Core operating profit grew nearly 22% to 145.2 million yen.
Earnings per share stood at 47.76 yen, up 30.5% versus 36.61 yen a year earlier.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze